Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
Go back to Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management| (NASDAQ: VANI) | Delayed: 1.23 +0.04 (3.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.19 | 52 Week High | $ | |||
| Open | $1.20 | 52 Week Low | $ | |||
| Day High | $1.24 | P/E | N/A | |||
| Day Low | $1.20 | EPS | $ | |||
| Volume | 45,601 | |||||
